Business
Our business is not dependent upon licenses, franchises, concessions, trademarks, royalty agreements, or labor contracts.
KEWAUNEE SCIENTIFIC CORP /DE/: Revenue grew 17.3% to $282M from $240M. Net income declined 15.7% to $9.618M from $11.4M. Free cash flow grew 16.5% to $14.7M from $12.62M. Operating margin contracted 146 bps to 5.93%. KEWAUNEE SCIENTIFIC CORP /DE/'s annual comparison also shows stock compensation grew faster than revenue; capital spending grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 17.3% to $282M from $240MOK
- Profitability — Net income declined 15.7% to $9.618M from $11.4MWatch
- Cash flow — Free cash flow grew 16.5% to $14.7M from $12.62MOK
- Margins — Operating margin contracted 146 bps to 5.93%Watch
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 15 salesWatch
Where the revenue comes from
Fiscal 2025, as KEWAUNEE SCIENTIFIC CORP /DE/ reports it. History and quarterly detail are in the app.
- Domestic$179.4M
- International$61.1M
Leadership changes
From KEWAUNEE SCIENTIFIC CORP /DE/'s own filings, the day they're filed.
- J. Jette Campbell · director · appointmenteff. 2025-09-10
Latest filings
- 8-K · Company announcement2026-08-27
- 8-K · Company announcement2026-08-26
- 8-K · Company announcement2026-08-25
- DEF 14A · Annual proxy (pay & governance)2026-07-07
- 10-K · Annual report2026-06-26
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about KEWAUNEE SCIENTIFIC CORP /DE/, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.